- Home
- DXCM vs ILMN Comparison
DXCM vs ILMN Comparison
Compare DXCM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | ILMN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 18.9B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DXCM | ILMN |
|---|---|---|
| Price | $65.89 | $130.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 15 |
| Target Price | $86.86 | ★ $117.27 |
| AVG Volume (30 Days) | ★ 5.2M | 1.7M |
| Earning Date | 10-30-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.75 | N/A |
| EPS | 1.80 | ★ 4.46 |
| Revenue | ★ $4,515,900,000.00 | $4,288,000,000.00 |
| Revenue This Year | $17.41 | N/A |
| Revenue Next Year | $12.78 | $2.08 |
| P/E Ratio | $36.59 | ★ $29.04 |
| Revenue Growth | ★ 14.21 | N/A |
| 52 Week Low | $54.11 | $68.70 |
| 52 Week High | $93.25 | $153.06 |
Technical Indicators
Market Signals| Indicator | DXCM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 58.38 |
| Support Level | $65.20 | $129.29 |
| Resistance Level | $68.19 | $137.09 |
| Average True Range (ATR) | 1.88 | 3.78 |
| MACD | 0.18 | -0.79 |
| Stochastic Oscillator | 48.79 | 50.64 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.